Terms: = Endocrine gland cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
2151 results:
1. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
2. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract] [Full Text] [Related]
3. Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2024; 15():1360615. PubMed ID: 38646521
[TBL] [Abstract] [Full Text] [Related]
4. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
5. Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival.
Leung PY; Chen W; Sari AN; Sitaram P; Wu PK; Tsai S; Park JI
World J Gastroenterol; 2024 Feb; 30(7):714-727. PubMed ID: 38515951
[TBL] [Abstract] [Full Text] [Related]
6. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L; Fischer LE; Heinemann V; Gieseler F; Hoehler T; Mayerle J; Quietzsch D; Reinacher-Schick A; Schenk M; Seipelt G; Siveke JT; Stahl M; Kaiser U; Waldschmidt DT; Dorman K; Zhang D; Westphalen CB; Boeck S; Haas M
ESMO Open; 2024 Apr; 9(4):102944. PubMed ID: 38503144
[TBL] [Abstract] [Full Text] [Related]
7. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
Ge W; Wang Y; Quan M; Mao T; Bischof EY; Xu H; Zhang X; Li S; Yue M; Ma J; Yang H; Wang L; Yu Z; Wang L; Cui J
Mol Cancer; 2024 Mar; 23(1):48. PubMed ID: 38459558
[TBL] [Abstract] [Full Text] [Related]
8. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract] [Full Text] [Related]
9. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
[TBL] [Abstract] [Full Text] [Related]
10. Cannabigerol Induces Autophagic Cell Death by Inhibiting egfr-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines.
Zeppa L; Aguzzi C; Morelli MB; Marinelli O; Giangrossi M; Luongo M; Amantini C; Santoni G; Nabissi M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396679
[TBL] [Abstract] [Full Text] [Related]
11. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
[TBL] [Abstract] [Full Text] [Related]
12. Feasibility of whole-exome sequencing in fine-needle aspiration specimens of papillary thyroid microcarcinoma for the identification of novel gene mutations.
Ma L; Gao L; Hu Y; Li X; Liu C; Ji J; Shi X; Pan A; An Y; Luo N; Xia Y; Jiang Y
Clin Genet; 2024 May; 105(5):567-572. PubMed ID: 38326996
[TBL] [Abstract] [Full Text] [Related]
13. Effects of rosmarinic acid and doxorubicine on an ovarian adenocarsinoma cell line (OVCAR3) via the egfr pathway.
Sarı U; Zaman F
Acta Cir Bras; 2024; 39():e390524. PubMed ID: 38324801
[TBL] [Abstract] [Full Text] [Related]
14. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract] [Full Text] [Related]
15. Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung cancer and High-Grade Serous Ovarian Carcinoma: A Case Report.
Lin J; Welch S; Sanatani M; Ramadan S
Curr Oncol; 2024 Jan; 31(1):558-565. PubMed ID: 38275832
[TBL] [Abstract] [Full Text] [Related]
16. Role of bio-flavonols and their derivatives in improving mitochondrial dysfunctions associated with pancreatic tumorigenesis.
Sharma V; Arora A; Bansal S; Semwal A; Sharma M; Aggarwal A
Cell Biochem Funct; 2024 Jan; 42(1):e3920. PubMed ID: 38269510
[TBL] [Abstract] [Full Text] [Related]
17. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro.
Huang YP; Yeh CA; Ma YS; Chen PY; Lai KC; Lien JC; Hsieh WT
Environ Toxicol; 2024 May; 39(5):2768-2781. PubMed ID: 38264921
[TBL] [Abstract] [Full Text] [Related]
18. The emerging roles of CEACAM6 in human cancer (Review).
Wu G; Wang D; Xiong F; Wang Q; Liu W; Chen J; Chen Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240103
[TBL] [Abstract] [Full Text] [Related]
19. 8-Br-cGMP suppresses tumor progression through egfr/PLC γ1 pathway in epithelial ovarian cancer.
Wu M; Mu C; Yang H; Wang Y; Ma P; Li S; Wang Z; Lan T
Mol Biol Rep; 2024 Jan; 51(1):140. PubMed ID: 38236447
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in egfr Stabilization and Ovarian cancer Cell Invasion.
Xia T; Ye F; Zhao W; Min P; Qi C; Wang Q; Zhao M; Zhang Y; Du J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203692
[TBL] [Abstract] [Full Text] [Related]
[Next]
